Saturday 17 October 2026 Export FLGT’s income statement to Excel — free account

Fulgent Genetics, Inc.

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%

Follow FLGT

Alert me

Market cap: $587.2M
P/E: 0.0×
Fwd P/E: −5.8×
Dividend yield: —
F-score: 4/9
Altman Z: 5.63
Beneish M: −2.35
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.68

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	5	2	—	—	—	—	2	2	—	2	2	—

Insider Ownership 37.12%

Capital & Financial Ratios $m

Market Cap 587.18

Revenue 323.93

Net Income (85.47)

Free Cash Flow (103.78)

Net Debt (257.03)

Current Ratio 6.34

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.80)

P/S ratio 1.71

P/B ratio 0.56

Past 5Y EPS Growth —

This Y EPS Growth (640.48%)

Next Y EPS Growth 39.21%

Next Y revenue growth 2.80%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 11.13%

10-year low 10-year high

P/B against its own 10 years 12.87%

10-year low 10-year high

EV/Sales against its own 10 years 13.86%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	424	258	336	257
Receivables	51	69	85	65
Inventory	—	—	—	—
Other	33	23	23	22
	508	354	550	455

	2023	2024	2025	Q'26
Payables	15	18	19	16
ST’ Debt	—	—	—	—
Other	26	30	32	32
	73	73	85	72

Compound Annual Growth %

	10y	5y	3y
Sales	42.15%	(5.21%)	(19.52%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	71.10%	14.22%	(4.48%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	71	85	—	—	—
’25	73	82	84	83	323
’24	64	71	72	76	283
’23	66	68	85	71	289
’22	320	125	106	68	619
’21	359	154	228	252	993
’20	8	17	102	295	422

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	7	(24)	—	—	—
’25	(4)	(30)	11	(78)	(102)
’24	7	4	(16)	25	21
’23	(8)	10	10	15	27
’22	188	11	21	33	254
’21	233	76	152	77	539
’20	1	(4)	9	134	141

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	(28)	—	—	—
’25	(9)	(37)	5	(83)	(124)
’24	3	(9)	(35)	21	(19)
’23	(10)	(2)	5	12	6
’22	183	8	16	29	235
’21	222	73	149	71	515
’20	1	(5)	(1)	110	106

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.80)	(1.05)	—	—	—
’25	(0.37)	(0.62)	(0.21)	(0.76)	(1.97)
’24	(0.45)	(0.29)	(0.48)	(0.19)	(1.41)
’23	(0.52)	(0.38)	(0.44)	(4.30)	(5.63)
’22	4.93	0.37	0.06	(0.80)	4.63
’21	6.52	2.59	3.93	3.34	16.38
’20	(0.09)	0.14	1.98	6.16	8.91

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.59	2.73	3.02	3.17	6.70	53.02	29.01	23.09	16.56	14.57	Analyst estimates 2026–2028 Powerpack
	High	12.15	13.90	5.56	16.50	56.53	189.89	101.98	44.09	29.91	31.04
People
People	Employees	70	98	123	139	429	645	1,012	1,184	1,313	1,315
	Revenue/emp, $m	0.26	0.19	0.17	0.23	0.98	1.54	0.61	0.24	0.22	0.25
Income, $m
Income, $m	Revenue	18	19	21	33	422	993	619	289	283	323
	Gross margin, %	63.22	54.35	49.90	56.63	78.70	78.29	59.28	36.12	37.82	40.56
	EBT	(4)	(3)	(5)	0	292	677	184	(174)	(52)	(70)
	EBT margin, %	(24.45)	(16.02)	(21.71)	1.26	69.17	68.24	29.73	(60.19)	(18.33)	(21.70)
	Net income	(5)	(3)	(6)	0	214	506	142	(175)	(44)	(62)
	Depreciation	1	2	2	2	4	19	37	142	19	19
Per share, $
Per share, $	Revenue	1.33	1.06	1.19	1.74	18.58	33.75	20.57	9.71	9.38	10.48
	Earnings	(0.31)	(0.15)	(0.25)	(0.02)	9.44	17.25	4.76	(5.63)	(1.41)	(1.97)
	Cash flow	0.32	0.08	(0.04)	0.29	6.20	18.31	8.42	0.91	0.70	(3.30)
	Capex	(0.28)	(0.30)	(0.16)	(0.06)	(1.55)	(0.81)	(0.61)	(0.72)	(1.32)	(0.73)
	Free cash flow	0.05	(0.23)	(0.20)	0.23	4.65	17.51	7.81	0.19	(0.63)	(4.04)
	Book value	3.97	3.05	2.85	4.42	25.09	39.65	42.19	38.05	37.35	35.96
	Shares, m	14	18	18	19	23	29	30	30	30	31
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	5.97	5.81	6.48	0.00	0.00	0.00
	P/S	8.36	4.01	2.67	7.42	2.80	2.98	1.49	3.02	1.97	2.51
	P/B	2.81	1.39	1.11	2.92	2.08	2.54	0.73	0.77	0.49	0.73
	EV/Sales	7.22	2.59	1.22	6.63	2.13	2.55	0.67	1.62	1.13	1.53
	EV/FCF	210.52	(12.06)	(7.40)	49.77	8.52	4.91	1.78	84.22	(16.96)	(3.97)
Cash, $m
Cash, $m	Operating cash flow	4	1	(1)	6	141	539	254	27	21	(102)
	Capex	(4)	(5)	(3)	(1)	(35)	(24)	(18)	(21)	(40)	(23)
	Free cash flow	1	(4)	(4)	4	106	515	235	6	(19)	(124)
Balance, $m
Balance, $m	Working capital	23	30	37	33	394	507	540	435	281	466
	Total debt	—	—	—	0	15	15	15	—	—	—
	Net debt	(21)	(26)	(31)	(28)	(284)	(435)	(511)	(424)	(258)	(336)
	Shareholders’ equity	54	54	51	83	569	1,166	1,270	1,133	1,129	1,107
Returns, %
Returns, %	ROA	(16.74)	(4.36)	(10.09)	(0.58)	54.31	51.27	10.76	(12.80)	(3.48)	(4.97)
	ROIC	1.71	(7.86)	(15.75)	(0.49)	63.62	57.83	14.71	(17.23)	(5.30)	(7.39)
	ROE	(17.94)	(4.62)	(10.65)	(0.61)	65.72	58.48	11.77	(13.97)	(3.78)	(5.41)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)	Compare
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)	Compare
PSNL Personalis, Inc.	$1.7B	— (loss-making)	— (loss-making)	+29.96% (above 0%: growing)	n/m	−123.46% (below 0%: shrinking)	21.21%	(150.25%)	Compare
OPK OPKO Health, Inc.	$1.2B	— (loss-making)	— (loss-making)	+4.32% (above 0%: growing)	n/m	+46.46% (above 0%: growing)	48.92%	(4.26%)	Compare
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+20.14% (above 0%: growing)	n/m	−43.33% (below 0%: shrinking)	77.11%	(2.96%)	Compare
FLGT Fulgent Genetics, Inc.	$587.2M	— (loss-making)	— (loss-making)	+4.38% (above 0%: growing)	n/m	+25.36% (above 0%: growing)	30.07%	(42.25%)
MYGN Myriad Genetics, Inc.	$416.1M	— (loss-making)	— (loss-making)	−10.51% (below 0%: shrinking)	n/m	+43.90% (above 0%: growing)	66.60%	(20.40%)	Compare
BDSX Biodesix, Inc.	$260.7M	— (loss-making)	— (loss-making)	+34.18% (above 0%: growing)	n/m	+72.75% (above 0%: growing)	82.06%	(20.06%)	Compare
XGN Exagen Inc.	$207.4M	— (loss-making)	— (loss-making)	+15.92% (above 0%: growing)	n/m	+211.34% (above 0%: growing)	61.27%	(8.64%)	Compare
Median of peers	$1.1B	—	—	+13.68%	—	+13.86%	63.94%	(11.94%)

All 52 Diagnostics & Research stocks →

Fulgent Genetics, Inc. (FLGT) key facts

Strength: Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024.
Fulgent Genetics, Inc. (FLGT) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, FLGT traded at $19.81, a market capitalization of $587.2 million.
Return on equity was −5.41% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 5.63 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.